Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer

Gynecologic Oncology

Volumn 71, Issue 2, 1998, Pages 190-195

  Eltabbakh, Gamal H ^a   Piver, M Steven ^a   Hempling, Ronald E ^a   Recio, Fernando O ^a   Blumenson, Leslie E ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; EPITHELIUM CELL; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RECURRENT DISEASE; SALVAGE THERAPY;

EID: 0032213064     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5112     Document Type: Article

References (22)

1. Thigpen J T, Vance R B, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer. 71:1993;1559-1564.
2. Sutton G P, Tehman F B, Einhorn L H, Roth L M, Blessing J A, Ehrlich C E. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol. 7:1989;223-229.
3. Ozols R F. Treatment of recurrent ovarian cancer: increasing options - "recurrent" results. J Clin Oncol. 15:1997;2177-2180.
4. Piver M S, Lele S B, Pastner B, McPhee M E. 1.5-5 years of uninterruptedcis. Gynecol Oncol. 27:1987;24-33.
5. Gynecol Oncol. 25:1986;383-385.
6. WHO Handbook for reporting results of cancer treatment. 1979;World Health Organization, Geneva.
7. Rustin G JS, Nelstrop A E, Crawford M, Ledermann J, Lambert H E, Coleman R, Johnson J, Evans H, Brown S, Oster W. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA 125. J Clin Oncol. 15:1997;172-176.
8. Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
10. Seltzer V, Vogel S, Kaplan B. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy includingcis. Gynecol Oncol. 21:1985;167-176.
11. Gershenson D M, Kavanagh J J, Copeland L J, Stringer C A, Morris M, Wharton J T. Re-treatment of patients with recurrent ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol. 73:1989;798-802.
12. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis J L Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
13. Markman M, Reichman B, Hakes T, Jones W, Lewis J L Jr, Rubin S, Almandrones L, Hoskins W. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 9:1991;1801-1805.
14. Markman M, Kennedy A, Webster K, Kulp B, Belinson J. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol Oncol. 65:1997;434-436.
15. Gershenson D M, Mitchell M F, Atkinson N, Silva E G, Kavanagh J J, Morris M, Burke T W, Warner D, Wharton J T. The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "maintenance" therapy reconsidered. Gynecol Oncol. 47:1992;7-13.
16. Hakes T B, Chalas E, Hoskins W J, Jones W B, Markman M, Rubin S, Chapman D C, Almandrones L, Lewis J L Jr. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol. 45:1992;284-289.
17. Bertelsen K, Jackobsen A, Stroyer J, Nielsen K, Sandberg E, Andersen J E, Ahrons S, Nyland M, Pedersen P H, Larson G, Rasmussen P, Kiaer H, Bichel P, Jaconsen M, Holund B. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, Adriamycin, andcis. Gynecol Oncol. 49:1993;30-36.
18. Meden H, Witkop Y, Kuhn W. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: Feasibility and toxicity. Anticancer Res. 17:1997;2221-2224.
19. Harris A L, Cantwell B MJ, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans R GB. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet. 335:1990;186-190.
20. Coates A, Gebski V, Bishop J F, Jeal P N, Woods R L, Snyder R, Tattersall M HN, Byrne M, Harvey V, Gill G, Simpson J, Drummond R, Browne J, Cooten R V, Forbes J F. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 317:1987;1490-1495.
21. Muss H B, Case D, Richards F I I, White D R, Cooper M R, Cruz J M, Powell B L, Spurr C L, Capizzi R L. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med. 325:1991;1342-1348.
22. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med. 317:1987;1388-1393.